



REFERENCES

- Abdel-Hamid, M.; Nafeh, M.A.; Medhat, A.; Shehata, M.; Mikhail, N.N.; Swife, Y.; et al.; (2000):** Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. *Am J Trop Med Hyg*;63:236-241.
- Akay, B. N.; Ekmekci, P.; et al.; (2006):** "Cutaneous, pulmonary and hepatic sarcoidosis associated with autoimmune complications during interferon-alpha treatment for hepatitis C virus infection." *J Eur Acad Dermatol Venereol* 20(4): 442-5.
- Andrade, L. J.; Atta, A. M.; et al.; (2008):** "Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review." *Braz J Infect Dis* 12(2): 144-8.
- Authier, F.J.; Pawlotsky, J.M.; Viard, J.P.; Guillevin, L.; Degos, J.D. and Gherardi, R.K. (1993):** High incidence of hepatitis C virus infection in patients with cryoglobulinemic neuropathy. *Ann Neurol*;34:749–750 (Abstract).
- Baron, S.; Tying, S.K.; Fleischmann, W.R.; Jr. et al.; (1991):** the Interferons. Mechanisms of action and clinical applications. *JAMA* 266, 1375–1383.
- Bekisz, J.; Schmeisser, H.; Hernandez, J.; et al.; (2004):** Human interferons alpha, beta and omega. *Growth Factors*; 22:243–51.
- Borden, E.C.; Lindner, D.; Dreicer, R.; Hussein, M. and Peereboom, D. (2000):** Second-generation interferons for cancer: clinical targets. *Semin. Cancer Biol.* 10, 125–144.



- Borg, F.A. and Isenberg, D. A. (2007):** "Syndromes and complications of interferon therapy." *Curr Opin Rheumatol* 19(1): 61-6.
- Chiaki Okuse, Hiroshi Yotsuyanagi, Yoshihiko Nagase, (2006):** Risk factors for retinopathy associated with interferon α -2b and ribavirin combination therapy in patients with chronic hepatitis C *World J Gastroenterol* June 21; 12(23): 3756-3759.
- Coverdale, S.A.; Khan, M. H.; et al. (2004):** "Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study." *Am J Gastroenterol* 99(4): 636-44.
- Cuthbertson, F.M.; Davies, M.; McKibbin, M. (2004):** Is screening for interferon retinopathy in hepatitis C justified? *Br J Ophthalmol*; 88:1518–1520.
- Damien Sène, Valérie Touitou, Bahram Bodaghi, David Saadoun, Gabriel Perlemuter, Nathalie Cassoux, Jean-Charles Piette, Phuc Le Hoang and Patrice Cacoub (2007):** Intraocular complications of IFN- α and ribavirin therapy in patients with chronic viral hepatitis C *World J Gastroenterol* June 14; 13(22): 3137-3140.
- Davis, G.L.; Esteban-Mur, R.; Rustgi, V.; et al.; (2003):** Interferon α -2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. *N Engl J Med*; 339:1493–1499.
- El-Serag, H.B.; Hampel, H.; Yeh, C. and Rabeneck, L. (2002):** Extrahepatic manifestations of hepatitis C among United States male veterans. *Hepatology*; 36:1439-45.
- Enudi, W. and Udolu, O.J. (2009):** "Neuropsychiatric Complications Associated with Interferon - Alpha -2b treatment of Malignant Melanoma." *Afr J Psychiatry (Johannesbg)* 12(3): 227-8.



- Ferri, C.; Zignego, A.L.; Pileri, S.A. and Cryoglobulins, J. (2002):** Clin Pathol; 55:4-13.
- Frank, C.; Mohamed, M.K.; Strickland, G.T. et al.; (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet mar 11, 355 (9207): 887.
- Fried, M.W. (2002):** Side effects of therapy of hepatitis C and their management. Hepatology; 36: S237–44.
- Gavis, G.I.; Wong, J.B.; Mchutchison, J.G.; Manns, M.P.; Harvey, J. and Albrecht, J. (2003):** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology; 38: 645-652.
- Guyer, D.R.; Tiedeman, J.; Yannuzzi, L.A.; et al.; (1993):** Interferon-associated retinopathy. Arch Ophthalmol; 111: 350-356.
- Hayasaka, S.; Fujii, M.; Yamamoto, Y.; et al.; (1995):** Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol; 79:150–2.
- Herbert, L.; Bonkovsky, and Savant Mehta. (2001):** Hepatitis C: a review and update. Journal of the American Academy of Dermatology 44: 159- 179.
- Hermine, O.; Lefrere, F.; Bronowicki, J.P.; et al.; (2002):** Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med; 347:89-94.

<http://www.drugs.com/pro/ribavirin.html>.



<http://www.hepcadvocacy.org/factsheets/Ribavirin.pdf>.

<http://www.medicinenet.com/interferon/article.htm>.

http://www.medicinenet.com/ribavirin-oral_capsules/page2.htm.

http://www.medscape.com/viewarticle/578705_2.

<http://www.rxlist.com/pegasys-drug.htm>

<http://www.rxlist.com/rebetol-drug.htm>.

Ikebe, T.; Nakatsuka, K.; Goto, M.; et al.,(1990): A case of retinopathy induced by intravenous administration of interferon. *Folia Ophthalmol Jpn (Ganka-Kiyo)* 41: 2291-2296.

Iman Zandieh, Mohamed Adenwalla, Cindy Cheong-Lee et al, (2006): Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. *World J Gastroenterol* ; 12(30): 4908-4910/

Isaacs, A. and Lindenmann, J. (1957): Virus interference. I. The interferon. *Proc. R. Soc. Lond. B. Biol. Sci.* 174, 258.

James Stecklberg, and Hepatitis, C. (2007): How common is sexual transmission? *Mayo Clinic staff.* Now 17.

Janet, R.; Wade Eric Snoeck, Frank Duff, Matthew Lamb, and Karin Jorga (2006): Pharmacokinetics of ribavirin in patients with hepatitis C virus *Br J Clin Pharmacol.* December; 62(6): 710–714.



Joel, A.; Schulman, Chanping Liang, Lakshmana, M.; Kooragayala and John King (2003):Posterior Segment Complications in Patients with Hepatitis C Treated with Interferon and Ribavirin, Ophthalmology; 110: 437– 442.

Joel, A.; Schulman, Chanping Liang, Lakshmana, M.; Kooragayala and John King (2003): Posterior Segment Complications in Patients with Hepatitis C Treated with Interferon and Ribavirin, Ophthalmology;110: 437–442.

John, M.; Levey, Bjorn Bjornsson, Barbara Banner, Mary Kuhns, Rajwant Malhotra, Nancy Whitman, Paul, L.; Romain, Thomas, G. Copley, and Herbert, L. and Bonkovsky (1994): Cryoglobulinemia in chronic hepatitis C infection: A clinico-pathological analysis of 10 cases and review of recent literature. Medicine (Baltimore) 73: 53-67.

Johnson, R.J.; Gretch, D.R.; Yamabe, H.; et al.; (1993): Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med; 328: 465-470.

Kawano, T.; Shigehira, M.; Uto, H.; Nakama, T.; Kato, J. and Hayashi, K. (1998); Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol; 91:309–313.

Kessel, A.; Rosner, I.; Zuckerman, E.; et al.; (2000): Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. J Rheumatol;27:610-2.



Lacaille, F.; Zylberberg, H.; Hagege, H.; et al.; (1998): Hepatitis C associated with Guillain-Barre syndrome. *Liver*; 18:49(Abstract)

Le Corguille, M.G.; Pochmalicki, et al.; (2007): "[Cardiovascular complications of alpha interferon]." *Gastroenterol Clin Biol* 31(12): 1081-4.

Louis d'Alteroche; Samuel Majzoub; Anne-Isabelle Lecuyer; et a; (2006): Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. *Journal of Hepatology* 44: 56–61.

Luciana Lofego Gonçalves, Alberto Queiroz Farias, Patrícia Lofego Gonçalves, Elbio Antonio D'Amico and Flair José Carrilho (2006): Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C, *World J Gastroenterol* July 28; 12(28): 4602-4603.

Masahiko Ayaki, (1994): Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C, *Br. J. Ophthalmol.* 1994;78;238.

Nadir, A.; Amin, A.; Chalisa, N. and van Thiel, D.H. (2000): Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. *J Viral Hepat*; 7: 466-470.

Nieves Fernandez – Arcas, Juan, Lopez- Siles, Sofia, Trapero, Angelo Ferraro, Agueda, Ibanez et al.; (2006): High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): Phylogenetic and epidemiological analysis. *Journal of Medical Virology*. Vol 78, issue 11, pages 1429-1435, 22 Sep.



- Nishiwaki, H.; Ogura, Y.; Miyamoto, K.; Matsuda, N. and Honda, Y. (1996):** Interferon_ induces leukocyte capillary trapping in rat retinal microcirculation. *Arch Ophthalmol*; 114:726–730.
- Rajiv Gupta, Sonali Singh, Rosa Tang, Thomas, A. Blackwell, and Jade, S. Schiffman, (2002):** Anterior ischemic optic neuropathy caused by interferon alpha therapy The American Journal of Medicine, Volume 112, Issue 8, 1 June, Pages 683-684.
- Reimi Tokai, Tomohiro Ikeda, Taku Miyaura, Keiko Sato (2001):** Interferon-Associated Retinopathy and Cystoid Macular Edema, *Arch Ophthalmol*. 119:1077-1079.
- Ruis, J.; Molitor, F. and Plagenhoef, J. (2002):** "Trends in hepatitis C and HIV infection among inmates entering prisons in Californis, 1994 versus 1999". *AIDS* 16 (16): 2236-8.
- Sabel, M.S. and Sondak, V. K. (2003):** Pros and cons of adjuvant interferon in the treatment of melanoma. *Oncologist* 8, 451–458.
- Salem, M.; Bazarah, Rusty Ritenour, Unil, T.; Patel, Geri Hirsch, Kevork, M.; Peltekian, Alan, F. and Cruess (2006):** Choroidal neovascularization with interferon associated retinopathy, *Annals of Hepatology*; 5(3): July-September: 172-176.
- Sandeep Mukherjee and Kinod, K.; Dhawan (2006):** Hepatitis C;6(7): October :243-49



- Shereef, Reda, (2007):** Egypt Among worst Hit by viral hepatitis. Daily News Egypt; 23:34-9
- Stehman-Breen, C.; Alpers, C.E.; Couser, W.G.; Willson, R.; Johnson, R.J. (1995):** Hepatitis C virus associated membranous glomerulonephritis. Clin Nephrol; 44:141-7.
- Strickland, G.T.; Elhefni, H.; Salman, T.; Warked, I. and Abdel- Hamid, M. (2002):** Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg.; 67 (4): 436-42.
- Sugano, S.; Suzuki, T.; Watanabe, M.; Ohe, K.; Ishii, K. and Okajima, T. (1998):** Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol. 93:2441–2444.
- Taiji Nagaoka, Eiichi Sato, Atsushi Takahashi, Shiro Yokohama, and Akitoshi Yoshida, (2007):** Retinal Circulatory Changes Associated with Interferon-Induced Retinopathy in Patients with Hepatitis C Investigative Ophthalmology & Visual Science, January 2007, Vol. 48: 368-375.
- Taniguchi, T. and Takaoka, A. (2001):** A weak signal for strong responses: interferon revisited. Nat. Rev. Mol. Cell Biol. 2, 378–386.
- Thomas, R.H. (2001):** Hypercoagulability syndromes. Arch Intern Med 2001; 161: 2433-2439.



Wilson, S.E.; Lee, W.M.; Murakami, C.; et al.; (1994): Mooren type hepatitis C virus associated corneal ulceration. Ophthalmology 1994, 101: 736-745.

www.mvretina.com/education/images/NVG.

Yamada,h..k., et al. ;(1994): Acute onset of ocular complications with interferon.lancet 343(8902): 914.

Zegans, M.E.; Anninger, W.; Chapman, C.; et al.; (2002): Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol; 13: 423-427.

Zuckerman, E.; Yeshurun, D. and Rosner, I. (2001): Management of hepatitis C virus-related arthritis. BioDrugs; 15:573-84.